Abstract

Provided are methods comprising expressing in a recombinant cell comprising a Cas gene a recombinant error-prone reverse transcriptase (RT) and a recombinant spacer RNA comprising a target sequence for mutagenesis of a DNA sequence in the Cas gene; making a mutagenized cDNA polynucleotide homologous to the DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence of the Cas gene in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant Cas protein, recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising the target sequence, and recombinant recombineering system.

IPC Classes  ?

• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms

Abstract

in vitroin vitroin vitro methods for screening, for producing or for testing compounds, a kit, a microfluidic or millifluidic channel, a process for encapsulating said microparticles, and a method for the quality control of a batch. Said microparticles are useful in the field of biological and medical applications.

IPC Classes  ?

• C08B 37/02 - DextranDerivatives thereof
• C08J 3/075 - Macromolecular gels
• C08L 5/02 - DextranDerivatives thereof
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

Abstract

The invention provides antibodies, and antigen-binding fragments thereof, that potently neutralize lyssavirus infection and the use of such antibodies. In particular, the invention provides methods of treatment of lyssavirus infection, such as rabies.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The invention relates to a new family of polymerases from archaeal viruses (PolARV) and their uses for nucleic acid synthesis, in particular untemplated nucleic acid synthesis.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

S. flexneriS. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and/or SFY.

IPC Classes  ?

• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C07H 1/00 - Processes for the preparation of sugar derivatives

Abstract

The application generally relates to recombinant genetic constructs comprising a recombinant measles virus expressing at least one rubella virus polypeptide, protein, antigen, or antigenic fragment thereof, and one mumps virus polypeptide, protein, antigen, or antigenic fragment. The application also relates to the uses of genetic constructs or viruses, and more particularly their applications for inducing immune responses and protection against rubella infection, mumps infection, and measles infection.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a method for selecting lymphocytes recognizing a conformational epitope of a protein antigen from a population of cells, comprising a step of identifying at least one lymphocyte binding to at least two separate peptides comprising sequences of the protein antigen, in particular at least three separate peptides comprising sequences of the protein antigen.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0781 - B cellsProgenitors thereof
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• G01N 15/149 - Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

NPXNPXNPX in new methods for the efficient delivery of molecular cargos inside target cells (in particular neurons and eye retina cells). The invention further relates to a Neurovita short interfering peptide suitable for neuroprotection and neuroregeneration and uses thereof, in particular a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Goods & Services

Stem cells for medical and scientific research; stem cells other than for medical and veterinary use; cell growth media for growing and cultivating cells, intended for use in scientific and medical research; engineered human biological organoids for medical and scientific research; engineered non-human biological organoids for medical and scientific research; bacteriological preparations (other than for medical and veterinary use) for scientific research use, active chemical ingredients; microbial and human bioresources; microbial and human bioresources for medical and scientific research; diagnostic preparations other than for medical or veterinary use; diagnostic preparations for use in research laboratories; chemical active ingredients for the manufacture of pharmaceuticals; diagnostic biomarker reagents for medical and scientific research; organoids on a chip; organs on a chip; organoids on a chip or organs on a chip for medical and scientific research; cell culture preparations intended for use in scientific and medical research using tissue cultures in a microfluidic device. Pharmaceutical and veterinary products; vaccines; disinfectants, antibacterials, anti-allergens, sporicides, virucides, products for destroying vermin, fungicides, herbicides; antibiotics; amino acids for medical and veterinary use; adjuvants for medical and veterinary use; biological preparations for medical and veterinary use; bacteriological preparations for medical and veterinary use; diagnostic products for medical and veterinary use; insecticides; cultivating microorganisms for medical and veterinary use; stem cells, stem cells for medical and veterinary use; biological, clinical, viral or fungal tissues, molecules and bacteria for medical and veterinary use; drugs for medical and veterinary use; pesticides; pharmaceutical preparations and substances; medicinal preparations and substances; Pharmaceutical and veterinary products sold on prescription or over the counter; enzymes for medical and veterinary use; preparations of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical or veterinary use. Scientific research instruments and apparatus for laboratories; downloadable computer software applications; online downloadable applications, especially via an international telecommunications network on all media (such as a computer, mobile telephone, tablet); simulators; measuring apparatus, instruments and devices; weighing apparatus and instruments; optical apparatus and instruments; test benches (checking apparatus); diagnostic apparatus for use in research laboratories; software; software for processing, consulting, classifying, collaboratively exploiting, sharing, annotating and analyzing scientific and medical research images and data; artificial intelligence software; recorded computer programs; downloaded computer programs; online downloadable electronic publications, especially via the Internet on all media (such as a computer, mobile telephone, tablet); downloadable online scientific electronic publications particularly via the Internet on all media (such as computers, mobile telephones, tablets); databases; scientific databases; downloadable image files; downloadable image files for scientific research use; computer platforms in the form of recorded or downloadable software; computer platforms in the nature of recorded or downloadable software for scientific and medical research; interfaces (for computers); computer interfaces for scientific and medical research; medical imaging software; software intended for use in tracking medical, biological, scientific and veterinary analyses; downloadable software applications intended for use in tracking medical, biological, scientific and veterinary analyses. Printing products (printed matter); photographs; instructional or teaching material in the scientific or medical field (except apparatus); printing blocks; printed matter, newspapers, periodicals, journals; printed matter, newspapers, periodicals, journals of a scientific or medical nature; albums; pamphlets; notebooks; catalogs; forms, printed; engravings, pictures, prints; books; handbooks [manuals]; publications; posters; leaflets; albums, brochures, notebooks, catalogs, forms, engravings, images, prints, books, manuals, publications, posters and leaflets of a scientific or medical nature. Advertising; bill-posting; creation of advertising material; distribution of advertising material [leaflets, prospectuses, printed matter, samples, derivatives]; distribution of advertising material [leaflets, prospectuses, printed matter, samples, derivatives]; dissemination of advertisements; advertisement dissemination; Promoting research (advertising); administrative and/or commercial services with respect to contracts for the transfer of innovation, technology, research results and intangible assets, advice relating thereto; market studies; business auditing (commercial analysis); administrative and/or commercial services with respect to research, negotiating, steering and coordinating research, institutional, industrial or commercial cooperation or partnerships, between industrial players, inventors and research centers; administrative and/or commercial services with respect to steering and coordinating the transfer and exchange of innovation, technology, research results; administrative and/or commercial services with respect to the management of research programs, innovation, technology, research results; public relations; commercial lobbying; sponsorship search; business networking; distribution of promotional material; acquisition, management, organization, administration, compilation, processing, systematization and update of data and databases; computer file management; compiling statistical data intended for use in scientific and medical research; corporate management assistance in the field of health, namely: assistance in business organization and general administration; news clipping services; compilation of statistics; retail services for downloadable image files of a scientific and medical nature; promoting public awareness in the field of health and medical research through awareness and information programs. Organizing collections of gifts for scientific and medical research; charitable fundraising for scientific and medical research; fundraising for scientific and medical research; information with respect to fundraising for scientific and medical research; information with respect to gifts for scientific and medical research; financial patronage operations; financial sponsorship for philanthropic purposes for scientific and medical research; funding searches; equity search; funding research and development projects; capital raising and capital raising negotiation services; investment search, investment management, financial investment services in the field of health and medical and scientific research; Real property management service. Education, teaching, tuition; training; cultural activities; scientific teaching; publishing of scientific works; film production; organization and conducting of colloquiums; organization and conducting of conferences, congresses; organization of exhibitions for cultural or educational purposes; organization of contests; publication of books; museum services (presentations, exhibitions); photography; information on education; videotaping; provision of non-downloadable videos online; tutoring; electronic desktop publishing; practical training; book lending; film projections; organization and conducting of seminars; organization and conducting of symposiums; training with respect to health; scientific training sessions; publishing scientific articles and specialist scientific information journals; editing, drafting reports and writing scientific texts; publication of scientific articles; organizing competitions in the scientific field; education, teaching and instruction services in the field of medicine, public health and scientific research; providing online seminars and training courses and online non-downloadable videos in the field of scientific and medical research; organization of competitions and award ceremonies. Research services, development in the industrial, scientific, medical, pharmaceutical and biological field; clinical studies (trials); scientific laboratory services; scientific analyses; developing diagnostic methods, namely services for developing medical diagnostic methods; development of new products for others, namely products or materials intended for use in patient care paths, diagnoses, prognostics or therapy; laboratory services, namely, providing laboratory analysis services in the medical, pharmaceutical, biological and veterinary fields; conducting scientific investigations for medical purposes to establish the origin of disease onset; scientific consultation and research services namely designing, conducting and managing research projects in the medical, pharmaceutical, biological and veterinary fields; research and consultation services in the medical, pharmaceutical, veterinary and biological fields; bacteriological and chemical laboratories; industrial and scientific research and analyses for medical, pharmaceutical, veterinary, biological purposes; developing, designing and updating software, computer programming, reconstitution of databases; research in the field of artificial intelligence; research laboratories; development of testing methods; scientific research and development; scientific study services; designing and developing monitoring, diagnostic, forecasting and analysis tools; electronic data storage; rental of downloadable image files of a scientific and medical nature; stem cell research; cell culture for scientific research purposes; research and development in the field of microorganisms and cells; research and development in the field of organoids and organs on a chip; analyses, testing and trial services for human tissue, cells, molecules and biological, clinical, viral, bacterial or fungal materials; scientific services relating to the isolation and cultivation of human tissues and cells; research and development in the field of microorganisms and cells; service for the storage, characterization and provision of biological resources; service for the storage, characterization and provision of biological resources for medical and scientific research purposes; hosting platforms on the Internet, hosting Web portals, temporary provision of non-downloadable software applications accessible via an Internet site; collaborative platform design services in the field of medical research and health; providing temporary use of non-downloadable computer software enabling users to enter, access, track, check and generate medical, biological, bacteriological, scientific and chemical information, analysis and reports; creation of databases. Medical services; medical analysis laboratory services; health services; consultation services with respect to medicine, pharmacy or bacteriology or virology in the field of human or animal health; medical screening; storing of human cells for medical use (biomedical services); provision of medical information; medical analysis services; providing medical, healthcare and medical services information on any medium, including online via the Internet and social networks; provision of advice, medical care and health services online on the Internet or on social networks; medical services, namely medical diagnostic, assessment, analysis services; medical assistance services; genetic analysis for medical use; medical examination services for individuals; vaccination services; medical analyses.

Abstract

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Ala- N-Methyl-L-Val- L-Ala-OMe, or a variant thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) SI-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response of infected animals. The invention is also directed to a exhaustive signature of Map and a mass spectrometry signature of Map presence or infection.

IPC Classes  ?

• A61P 31/06 - Antibacterial agents for tuberculosis
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

Schistosoma haematobium, Opisthorchis viverriniSchistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis and provide evidence of fluke-borne infection of parasitized vertebrate hosts.. The invention provides viruses, nucleic acids, proteins, peptides, and antibodies useful for diagnosis, treatment, and prevention of viral infection and associated diseases.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I). The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/52 - Purines, e.g. adenine
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• C07D 471/04 - Ortho-condensed systems
• C07D 473/00 - Heterocyclic compounds containing purine ring systems
• C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
• C07D 487/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems

Abstract

The invention relates to the first hydrolase that specifically digests the archaeal type of a peptidoglycan (PG), the major component of the cell wall of methanogens, named Talosaminidase. The enzyme consists of a signal peptide, several bacterial IG domains, a glycosyl hydrolase, several archaeal PG binding domains and a peptidase domain. The double enzymatic activity for the glycosyl hydrolase and the peptidase maximizes the lysis of archaeal cells with a cell wall of the archaeal PG-type. Engineering the enzyme by removing the signal peptide and bacterial IG domains and keeping only the archaeal PG binding, glycosyl hydrolase and peptidase made the enzyme easier to express and purify, without negatively influencing the enzymatic activity. Therefore, engineered Talosaminidase can be used to regulate populations of archaeal methanogens in the industrial, agricultural and medical settings, and consequently methane production.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 31/04 - Antibacterial agents
• C12N 9/50 - Proteinases
• C12N 9/52 - Proteinases derived from bacteria

Abstract

A recombinant lentiviral vector genome comprising a polynucleotide encoding a fusion polypeptide, wherein said fusion polypeptide comprises, arranged from N-terminal to C-terminal ends: a first polypeptide comprising (i) an MHC-ll-associated light invariant chain (li), or (ii)) the transmembrane domain of the transferrin receptor (TfR) and at least one antigenic polypeptide of a pathogen. The invention also relates to a lentiviral vector and pharmaceutical compositions comprising it.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/06 - Antibacterial agents for tuberculosis
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/74 - Major histocompatibility complex [MHC]
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/09 - Tumour cells
• C12N 15/86 - Viral vectors

Abstract

Here, the inventors use genomics to discover a new family of lanthipeptides from Actinobacteria dedicated to anti-phage defense. They demonstrate that a specific family of metabolic pathways that produce unknown class I lanthipeptides are encoded near known anti-phage defense systems or within mobile genetic elements, indicating their anti-phage function. Furthermore, the inventors show that the heterologous expression of these pathways in Streptomyces albus (a model strain of Actinobacteria) confers anti-phage defense. The experimental results show that different lanthipeptides of this family confer a selective protection against phages, without compromising the cell viability. The inventors also have identified a specific regulatory system that controls the expression of "defensive lanthipeptides" in Actinobacteria and use this to demonstrate their anti-phage function in a native strain. Finally, the inventors explore the anti-phage mechanism of action of these compounds. Thus the present invention relates to a new class of anti-phage natural peptides.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/54 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Abstract

Lachnospiraceae spp and Ruminococcus lactaris new strains of bacteria for use solely or in combination, in the treatment and prevention of memory decline in an individual, in particular declines of aging or Alzheimer's disease-related origin. Compositions, in particular, an oral composition, including the Lachnospiraceae spp and Ruminococcus lactaris strains and uses thereof.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to ApsA and ApsB proteins, including ApsA-like and ApsB-like proteins, and to their involvement in the mobilisation of the carbapenemase blaOXA-48 gene from the pOXA-48 plasmid into the chromosome. The ApsA and ApsB proteins combine a nuclease/helicase protein and a novel type of Argonaute-like protein to cleave DNA. The invention encompasses compositions comprising ApsA and ApsB proteins, including ApsA-like and ApsB- like proteins, antibodies against these proteins, nucleic acids encoding these proteins, vectors expressing these proteins and cells and kits comprising these nucleic acids, vectors and/or proteins. The invention further encompasses methods for making and using these compositions for diagnostic assays and for genetic engineering.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 1/08 - Reducing the nucleic acid content
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to the human protein Family with sequence similarity 118 member B (FAM118B). In particular, the present invention relates to the activation, or the inhibition of the activity or effect provided by FAM118B, for modulating the inflammatory response. In particular, it is provided the use of activator of FAM118B, or an activator of the biological effects provided by FAM118, for inducing, sustaining, or enhancing an inflammatory process, in particular an inflammatory process associated with a cancer, a bacterial infection, or a viral infection. In particular, it is also provided the use of an inhibitor of FAM118B, or an inhibitor of the biological effects provided by FAM118B, for inhibiting, or reducing an inflammatory process, more particularly for inducing the resolution of an inflammatory process.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Goods & Services

Pharmaceutical and veterinary products; vaccines; disinfectants, antibacterials, anti-allergens, sporicides, virucides, products for destroying vermin, fungicides, herbicides; antibiotics; amino acids for medical and veterinary use; adjuvants for medical and veterinary use; biological preparations for medical and veterinary use; bacteriological preparations for medical and veterinary use; diagnostic products for medical and veterinary use; insecticides; cultivating microorganisms for medical and veterinary use; stem cells, stem cells for medical and veterinary use; biological, clinical, viral or fungal tissues, molecules and bacteria for medical and veterinary use; drugs for medical and veterinary use; pesticides; pharmaceutical preparations and substances; medicinal preparations and substances; Pharmaceutical and veterinary products sold on prescription or over the counter; enzymes for medical and veterinary use; preparations of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical or veterinary use Organizing collections of gifts for scientific and medical research; charitable fundraising for scientific and medical research; fundraising for scientific and medical research; information with respect to fundraising for scientific and medical research; information with respect to gifts for scientific and medical research; financial patronage operations; financial sponsorship for philanthropic purposes for scientific and medical research; funding searches; equity search; funding research and development projects; capital raising and capital raising negotiation services; investment search, investment management, financial investment services in the field of health and medical and scientific research; Real property management service Education, teaching, tuition; training; cultural activities; scientific teaching; publishing of scientific works; film production; organization and conducting of colloquiums; organization and conducting of conferences, congresses; organization of exhibitions for cultural or educational purposes; organization of contests; publication of books; museum services (presentations, exhibitions); photography; information on education; videotaping; provision of non-downloadable videos online; tutoring; electronic desktop publishing; practical training; book lending; film projections; organization and conducting of seminars; organization and conducting of symposiums; training with respect to health; scientific training sessions; publishing scientific articles and specialist scientific information journals; editing, drafting reports and writing scientific texts; publication of scientific articles; organizing competitions in the scientific field; education, teaching and instruction services in the field of medicine, public health and scientific research; providing online seminars and training courses and online non-downloadable videos in the field of scientific and medical research; organization of competitions and award ceremonies Research services, development in the industrial, scientific, medical, pharmaceutical and biological field; clinical studies (trials); scientific laboratory services; scientific analyses; developing diagnostic methods, namely services for developing medical diagnostic methods; development of new products for others, namely products or materials intended for use in patient care paths, diagnoses, prognostics or therapy; laboratory services, namely, providing laboratory analysis services in the medical, pharmaceutical, biological and veterinary fields; conducting scientific investigations for medical purposes to establish the origin of disease onset; scientific consultation and research services namely designing, conducting and managing research projects in the medical, pharmaceutical, biological and veterinary fields; research and consultation services in the medical, pharmaceutical, veterinary and biological fields; bacteriological and chemical laboratories; industrial and scientific research and analyses for medical, pharmaceutical, veterinary, biological purposes; developing, designing and updating software, computer programming, reconstitution of databases; research in the field of artificial intelligence; research laboratories; development of testing methods; scientific research and development; scientific study services; designing and developing monitoring, diagnostic, forecasting and analysis tools; electronic data storage; rental of downloadable image files of a scientific and medical nature; stem cell research; cell culture for scientific research purposes; research and development in the field of microorganisms and cells; research and development in the field of organoids and organs on a chip; analyses, testing and trial services for human tissue, cells, molecules and biological, clinical, viral, bacterial or fungal materials; scientific services relating to the isolation and cultivation of human tissues and cells; research and development in the field of microorganisms and cells; service for the storage, characterization and provision of biological resources; service for the storage, characterization and provision of biological resources for medical and scientific research purposes; hosting platforms on the Internet, hosting Web portals, temporary provision of non-downloadable software applications accessible via an Internet site; collaborative platform design services in the field of medical research and health; providing temporary use of non-downloadable computer software enabling users to enter, access, track, check and generate medical, biological, bacteriological, scientific and chemical information, analysis and reports; creation of databases Medical services; medical analysis laboratory services; health services; consultation services with respect to medicine, pharmacy or bacteriology or virology in the field of human or animal health; medical screening; storing of human cells for medical use (biomedical services); provision of medical information; medical analysis services; providing medical, healthcare and medical services information on any medium, including online via the Internet and social networks; provision of advice, medical care and health services online on the Internet or on social networks; medical services, namely medical diagnostic, assessment, analysis services; medical assistance services; genetic analysis for medical use; medical examination services for individuals; vaccination services; medical analyses

Goods & Services

(1) Produits pharmaceutiques et vétérinaires; vaccins; désinfectants, antibactériens, anti-allergènes, sporicides, virucides, produits pour la destruction d'animaux nuisibles, fongicides, herbicides; antibiotiques; aminoacides à usage médical et vétérinaire; adjuvants à usage médical et vétérinaire; préparations biologiques à usage médical et vétérinaire; préparations bactériologiques à usage médical et vétérinaire; produits pour le diagnostic à usage médical et vétérinaire; insecticides; culture de micro-organismes à usage médical et vétérinaire; cellules souches, cellules souches à usage médical et vétérinaire; tissus, molécules et bactéries biologiques, cliniques, virales ou fongiques à usage médical et vétérinaire; drogues à usage médical et vétérinaire; pesticides; substances et préparations pharmaceutiques; substances et préparations médicinales; produits pharmaceutiques et vétérinaires vendus sur ordonnance ou en vente libre; enzymes à usage médical et vétérinaire; préparations de micro-organismes à usage médical ou vétérinaire; réactifs de biomarquage pour le diagnostic à usage médical ou vétérinaire. (1) Organisation de collectes de dons pour la recherche scientifique et médicale; collecte de bienfaisance pour la recherche scientifique et médicale; collecte de fonds pour la recherche scientifique et médicale; informations en matière de collecte de fonds pour la recherche scientifique et médicale; informations en matière de dons pour la recherche scientifique et médicale; opérations de mécénat financier; parrainage financier à but philanthropique pour la recherche scientifique et médicale; recherches de financements; recherche de capitaux propres; financement de projets de recherches et développement; services de levées de capitaux et de négociations de levées de capitaux; recherche d'investissement, gestion d'investissement, services financiers d'investissement dans le domaine de la santé et de la recherche médicale et scientifique; service de gestion de biens immobiliers. (2) Education, enseignement, instruction; formation; activités culturelles; enseignement scientifique; édition d'ouvrages scientifiques; production de films; organisation et conduite de colloques; organisation et conduite de conférences, congrès; organisation d'expositions à buts culturels ou éducatifs; organisation de concours; publication de livres; services de musées (présentations, expositions); photographie; information en matière d'éducation; enregistrement (filmage) sur bande vidéo; mise à disposition en ligne de vidéos non téléchargeables; tutorat; micro-édition; formation pratique; prêt de livres; projections de films; organisation et conduite de séminaires; organisation et conduite de symposiums; formations en matière de santé; formations scientifiques; services de publication d'articles scientifiques et de revues spécialisées en information scientifique; édition, établissement de rapports et rédaction de textes scientifiques; publication d'articles scientifiques; organisation de concours dans le domaine scientifique; services d'éducation, d'enseignement et d'instruction dans le domaine médical, de la santé publique et de la recherche scientifique; mise à disposition de séminaires et de cours de formation en ligne et par vidéos en ligne non téléchargeables dans le domaine de la recherche scientifique et médicale; organisation de concours et de cérémonies de remise de prix. (3) Services de recherche, de développement dans le domaine industriel, scientifique, médical, pharmaceutique, biologique; études (essais) cliniques; services de laboratoires scientifiques; analyses scientifiques; élaboration de méthode de diagnostic, à savoir services de développement de méthodes de diagnostic médical; développement de nouveaux produits pour des tiers à savoir produits ou matériels destinés à être utilisés dans le cadre du parcours de soin des patients, du diagnostic, du pronostic ou thérapeutique; services de laboratoires, à savoir, fourniture de services d'analyses de laboratoire de dans les domaines médical, pharmaceutique, biologique et vétérinaire; conduite d'investigations scientifiques à des fins médicales pour établir l'origine du déclenchement des maladies; services de consultation scientifique et de recherche à savoir conception, conduite et gestion de projets de recherche dans les domaines médical, pharmaceutique, biologique et vétérinaire; services de recherches et de consultations dans les domaines médical, pharmaceutique, vétérinaire, biologique; laboratoires bactériologiques et chimiques; recherches et analyses industrielles et scientifiques à but médical, pharmaceutique, vétérinaire, biologique; élaboration, conception et mise à jour de logiciels, programmation pour ordinateur, reconstitution de bases de données; recherche dans le domaine de l'intelligence artificielle; laboratoires de recherche; développement de méthodes d'essai; recherche et développement scientifique; services d'études scientifiques; conception et développement d'outils de suivi, de diagnostic, de prédiction et d'analyse; stockage électronique de données; service de location de fichiers d'images téléchargeables à caractère scientifique et médical; recherche sur les cellules souches; culture de cellules à des fins de recherche scientifique; recherche et développement dans le domaine des micro-organismes et cellules; recherche et développement dans le domaine des organoïdes et organes à puces; service d'analyses, de tests et d'essai de tissus humains, de cellules, molécules et de matériel biologique, clinique, viral, bactérien ou fongique; services scientifiques en matière d'isolement et de culture de cellules et tissus humains; recherche et développement dans le domaine des micro-organismes et des cellules; service de stockage, caractérisation et mise à disposition de ressources biologiques; service de stockage, caractérisation et mise à disposition de ressources biologiques à des fins de recherche médicale et scientifique; plateformes d'hébergement sur internet, hébergement de portails web, mise à disposition temporaire d'applications logicielles non téléchargeables accessibles par le biais d'un site internet; services de conception de plateformes collaboratives dans le domaine de la recherche médicale et de la santé; mise à disposition temporaire de logiciels informatiques non téléchargeables permettant aux utilisateurs d'entrer, d'accéder, de suivre, de contrôler et de générer des informations, des analyses et des rapports médicaux, biologiques, bactériologiques, scientifiques et chimiques; création de bases de données. (4) Services médicaux; services de laboratoires d'analyse médicale; services de santé; services de consultation en matière de médecine, de pharmacie ou de bactériologie ou virologie dans le domaine de la santé humaine ou animale; dépistage médical; entreposage de cellules humaines à usage médical (services biomédicaux); mise à disposition d'informations médicales; services d'analyses médicales; fourniture de renseignements médicaux, de soins de santé et de services médicaux sur tout support, y compris en ligne par le biais d'internet et des réseaux sociaux; fourniture de conseils, de soins médicaux et de services de santé en ligne sur Internet ou sur les réseaux sociaux; services médicaux, à savoir services de diagnostics, d'évaluations, d'analyses médicales; services d'assistance médicale; analyses génétiques à usage médical; services d'examen médical pour particuliers; services de vaccination; analyses médicales.

Goods & Services

Pharmaceutical and veterinary preparations; Vaccines; Disinfectants, antibacterials, anti-allergens, sporicides, virucides, products for destroying of damaging animals, fungicides, herbicides; Antibiotics; Amino acids for medical and veterinary purposes; adjuvants used for medical and veterinary uses; Biological preparations for medical and veterinary purposes; Bacteria preparations for medical and veterinary purposes; Diagnostic preparations for medical and veterinary purposes; Insecticides; Cultures of microorganisms for medical and veterinary uses; Stem cells, Stem cells for medical and veterinary purposes; Biological, clinical, viral or fungal tissues, molecules and bacteria For medical and veterinary uses; Drugs for medical purposes and Drugs for veterinary use; Pesticides; Pharmaceutical preparations and substances; Medicinal preparations and substances; Enzymes for medical and veterinary purposes; Preparations of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical or veterinary use. Arranging of donation collections for scientific and medical research; Charitable fundraising for scientific and medical research; Fundraising for scientific and medical research; Information on fundraising for scientific and medical research; Information on donations for scientific and medical research; Financial sponsorship; Financial sponsorship for philanthropic purposes for scientific and medical research; Fundraising; Equity research; Financing of research and development projects; Capital raising and capital raising negotiation; Investment research, investment management, financial investment in the field of health and of medical and scientific research; Real-estate management services. Education, teaching, tuition; Training; Conducting of cultural activities; Scientific instruction; Publishing of scientific works; Film production services; Arranging and conducting of colloquiums; Arranging and conducting of conferences and congresses; Arranging of exhibitions for cultural or educational purposes; Arranging of contests; Publication of books; Museum facilities (Providing -) [presentation, exhibitions]; Photography; Information (education-); Videotaping; Providing online videos, not downloadable; Tutoring; Electronic desktop publishing; Practical training [demonstration]; Lending library services; Film screenings; Arranging and conducting of seminars; Arranging and conducting of symposiums; Providing of training on health; Scientific training; Publishing of scientific articles and specialised journals in scientific information; Publishing, reporting and writing of scientific texts; Publishing of scientific papers; Arranging of contests In the scientific field; Teaching, Teaching and Teaching In the medical, public health and scientific research field; Providing of seminars and training courses online and via online non-downloadable videos in the following fields: Scientific and medical research; Organisation of competitions and award ceremonies. Research and development in the industrial, scientific, medical, pharmaceutical and biological fields; Clinical trials; Scientific laboratory services; Scientific analysis; Development of diagnostic methods, namely Development of medical diagnostic methods; Development of new products, for others, namely goods or materials for use in the context of care pathways for patients, diagnosis, prognosis or therapy; Laboratory services, namely Laboratory analysis in the medical, pharmaceutical, biological and veterinary field; Conducting of scientific investigations for medical purposes to establish the origin of diseases; Scientific consultation and research, namely Design, conducting and management of research projects in the medical, pharmaceutical, biological and veterinary field; Research In the medical, pharmaceutical, veterinary and biological field; Advice and information In the field of biology; Bacteriological and chemical laboratories; Industrial analysis and research services For medical, pharmaceutical, veterinary, biological purposes; Design and updating of software, Computer programming, Recovery of computer data; Research in the field of artificial intelligence technology; Research laboratories; Development of testing methods; Scientific research and development; Provision of surveys [scientific]; Design and development of monitoring, diagnostic, predictive and analytical tools; Electronic data storage; Rental of downloadable scientific and medical images; Stem cell research; Culturing of cells for scientific research purposes; Research and development in the field of microorganisms and cells; Research and development In the field of organoids and organs-on-a-chip; Analysis, testing and trial of human tissues, cells, molecules and biological, clinical, viral, bacterial or fungal materials; Scientific services relating to the isolation and cultivation of human tissues and cells; Research and development in the field of microorganisms and cells; Storage, characterisation and providing of biological resources; Storage, characterisation and providing of biological resources For scientific and medical research purposes; Internet hosting platforms, web portal hosting, providing of temporary use of non-downloadable computer software applications accessible via a website; Design of collaborative platforms in the medical and health field; Providing of temporary use of non-downloadable computer software enabling users to enter, access, track, control and generate medical, biological, bacteriological, scientific and chemical information, analysis and reports. Medical services; Medical laboratory analysis; Medical services; Consultancy relating to medicine, pharmacy, bacteriology or virology in the field of human or animal health; Medical screening; Biomedical services, namely, the storage of human cells for medical use; Providing medical information; Medical analysis services; Providing of medical intelligence, healthcare and medical services on media of all kinds, including online via the internet and social networks; Providing of advice, medical care and healthcare services online on the internet or via social networks; Awareness and information schemes In the field of health and medical research; Medical services, namely medical diagnosis, evaluations, medical analysis; Medical assistance; Genetic testing for medical purposes; Medical examination of individuals; Vaccination services; advising In the medical, pharmaceutical and veterinary field; Medical analysis.

Abstract

1234523231677 represent independently a hydrogen or a methyl; - wherein n and m are integers, independently selected among 1 to 3; and - wherein p is an integer selected among 1 and 2.

IPC Classes  ?

• C07D 221/20 - Spiro-condensed ring systems
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Abstract

The invention relates to an engineered DNA polymerase D (PolD) and its use for nucleic acid amplification including reverse transcription of RNA.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

A dual AAV vector strategy encoding isoform 5 of otoferlin cDNA that has been split into two expression cassettes both packaged in—and delivered by—an AAV8 capsid can efficiently deliver the otoferlin cDNA to the inner hair cell (IHC). Moreover, the use of the CMV promoter in one of the two AAV8 vectors provides a significant expression of otoferlin in these particular cells. As the AAV serotype and the type of promoter used are two key elements that have a significant effect on the transduction efficiency, this vector system provides optimal therapeutic benefit in patients suffering from DFNB9 deafness. To further improve this therapeutic effect, otoferlin-encoding dual vector constructs to identify enhanced transfection rate and a very effective in vitro and in vivo otoferlin expression in mature cochlea of DFNB9 mice models, leading to the restoration of their hearing.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/16 - Otologicals
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/86 - Viral vectors

Abstract

The invention relates to nucleic acid constructs which comprises a DNA molecule encoding a recombinant L or S segment of a Mopeia virus (MOPV), as well as an expression cassette or a vector comprising them, an eukaryotic cell comprising them, and a method of expressing one or more polypeptide(s) or protein(s) that is(are) heterologous to Mopeia virus (MOPV) or fragments thereof and/or producing recombinant live attenuated Mopeia virus (MOPV) expressing one or more polypeptide(s) or protein(s) that is(are) heterologous to MOPV or fragments thereof, in a eukaryotic host cell, using in particular the nucleic acid constructs of the invention. The invention also relates to a composition comprising viral particles obtained from such a method, a viral particle obtained from such a method and a set of nucleic acid constructs or expression cassettes or vectors comprising them, wherein the set comprises at least one nucleic acid construct or expression cassette or vector comprising it, which encodes a recombinant L segment of a Mopeia virus (MOPV), and one nucleic acid construct or expression cassette or vector comprising it, which encodes a recombinant S segment of a Mopeia virus (MOPV) that encodes a MOPV nucleoprotein (NP) having attenuated exonuclease activity, wherein one or both nucleic acid constructs or expression cassettes or vectors comprise(s) a polynucleotide encoding a polypeptide or a protein that is heterologous to MOPV and the latter is different from a non-MOPV GPC when on the S segment, and wherein the positions where the polynucleotide encoding at least one polypeptide or protein that is heterologous to MOPV is inserted in the said nucleic acid constructs or expression cassettes or vectors are peculiar.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors
• A61K 39/12 - Viral antigens

Abstract

The invention relates to the field of cancer therapy, especially by inducing cell death of malignant B cells by activating RIPK3 signaling pathway in these cells. The invention thus involves activating RIPK3 signaling pathway in malignant B cells for treating a patient in need thereof. The activation of RIPK3 signaling pathway in malignant B cells has in particular been shown to be beneficial against tumor growth, in particular when combined with an agonist of MLKL (like type I IFN) and/or a caspase inhibitor that optimize direct tumor cell death and subsequent anti-tumor immune response.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 38/21 - Interferons
• A61K 38/45 - Transferases (2)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Plasmodium falciparum50Plasmodium falciparum50P. falciparum50P. falciparum5050 value= 0.99 µM. The present invention thus relates to the use of ravidasvir, velpatasvir, and elbasvir for blocking transmission of Plasmodium gametocytes.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/65 - Tetracyclines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 33/06 - Antimalarials

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome -related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The invention concerns a multivalent immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV), wherein each valence is constituted by a recombinant live attenuated Mopeia virus in which the MOPV nucleoprotein (NP) has attenuated exonuclease activity and the encoded glycoprotein precursor (GPC) is from a New World arenavirus selected from one of the following arenaviruses: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV). The invention also concerns a combination of active ingredients, a composition or vaccine, or a therapeutically effective composition, comprising such recombinant live attenuated Mopeia viruses (MOPV) for use in eliciting a protective immune response in a mammalian host against a New World arenavirus infection. The invention also concerns a method of preparing such recombinant live attenuated Mopeia viruses (MOPV) in a eukaryotic host cell and a method of preparing a multivalent, in particular a pentavalent, immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV) expressing a GPC protein of a New World arenavirus selected among: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV).

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A composition comprising an oil phase comprising notably a botanical extract and an oil in water emulsion comprising said composition. The composition can include one or more non-VOC bio-based solvents chosen from the group of esters of aliphatic monocarboxylic acids, two or more bio-based non-ionic surfactants, and an anti-foaming agent. It further relates to the use of such composition and emulsion as an insecticidal agent, in particular a larvicidal agent.

IPC Classes  ?

• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01P 7/04 - Insecticides

Abstract

The invention relates to immunocytokines comprising an anti-CTLA-4 antibody fused to a Treg-specific IL-2 receptor antagonist and their use to selectively deplete tumor-associated Tregs, in particular for treating cancer.

IPC Classes  ?

• A61K 38/20 - Interleukins
• C07K 14/55 - IL-2
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Clostridioides difficileClostridioides difficile.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to a method for reprogramming CD8+ T cells to enhance their therapeutic potential and its applications, in particular in adoptive T cell therapy for the treatment of infectious diseases and cancer.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to anti-ACE2 peptidase domain single domain antibodies. Further, the present invention relates to anti-ACE2 single domain antibodies comprising the CDR regions of the present single domain antibodies, polypeptides comprising thereof such as multimers thereof, and fusion proteins comprising thereof, as well as pharmaceutical compositions comprising the single domain antibodies, the polypeptides comprising thereof such as the multimeric single domain antibodies thereof, or the fusion proteins comprising thereof, and their use for treating diseases caused by a virus having ACE2 as receptor.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A method for genotyping a plasmodium comprising: (a) providing a sample containing a Plasmodium; and (b) detecting the presence of an increased copy number of the genomic plasmepsin2-3 cluster. A method for the detection of a plasmodium infection in a patient comprising: (a) providing a blood sample from a patient and (b) detecting the presence or absence of an increased copy number of the genomic plasmepsin2-3 cluster in the blood sample. Kits for genotyping a plasmodium and/or detection of a plasmodium infection. Methods of treating a plasmodium infection.

IPC Classes  ?

• C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The invention relates to the field of immunity against coronaviruses. In this respect, the invention provides a lentiviral-based immunogenic agent that is suitable for use in boost or target immunization treatment in a subject, in particular a human subject, who had previously developed an immunity against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) based on: (i) vaccination with the first generation of vaccines against SARS-CoV-2 infection or disease such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine composition against SARS-CoV-2 infection or disease, in particular a protein- or an mRNA-based vaccine, or (ii) SARS-CoV-2-induced or correlated disease. The invention accordingly concerns a lentiviral-based immunogenic agent that in particular may help overcome the deficiencies of available vaccines against SARS-CoV-2, especially may be efficient in overcoming the waning immune response or insufficient cellular memory response observed after immunization with available first generation of vaccines such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine, in particular protein or mRNA vaccine, by triggering a mucosal humoral and cellular immune response against coronaviruses, including a long-lasting immune response.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants

Abstract

The present invention relates to an in vitro method for analyzing DNA interactions and kits for implementing said method. The method of the invention is more particularly useful for analyzing interactions between i) single-strand DNA (ssDNA) and ii) double-strand or single- strand DNA (dsDNA or ssDNA).

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The invention discloses a lentiviral vector and lentiviral vector particles for treating hepatitis B infection. The lentiviral vector and particles of the invention contain a nucleotide sequence coding an hepatitis B virus antigen. The large S antigen of hepatitis B virus was in particular selected as candidate and can be applied in pharmaceutical compositions or vaccines for treating and/or preventing hepatitis B virus infection or treating and/or preventing diseases caused by hepatitis B virus infection, which has excellent therapeutic and preventive effects in subjects in need thereof.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/20 - Antivirals for DNA viruses
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A medical device for the delivery of a therapeutic agent by bioprinting including a rod body including a bioprinting cartridge arranged near the distal end of the rod body including a top layer including a solution containing a therapeutic agent; and an absorbent compound capable of converting light energy from laser radiation into thermal energy and arranged to cause heating of the solution including a therapeutic agent to cause a jet of the solution; an optical fiber extending longitudinally within a lumen of the rod body to deliver laser flow onto the absorbing compound.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes

Abstract

A recombinant lentiviral vector comprising a coding sequence for an OR protein fused to a coding sequence for a fluorescent protein or a subunit of a fluorescent protein, and a promoter active in human cells operatively linked to the coding sequences. A recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription. A recombinant eukaryotic cell comprising a genomically integrated DNA copy of the recombinant lentiviral vector. A method of observing lentiviral DNA in a eukaryotic cell, comprising: providing a recombinant eukaryotic cell that produces a fusion protein comprising an OR protein, fused to a fluorescent protein or a subunit of a fluorescent protein: infecting the recombinant eukaryotic cell with a recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription, under conditions sufficient for reverse transcription of the recombinant lentiviral genome comprising an ANCH sequence: allowing the OR protein to bind to the ANCH sequence; and detecting the fluorescent protein or subunit of the fluorescent protein to thereby observe the lentiviral DNA in the eukaryotic cell. This tool can be suitable also for in vivo applications (e.g. humanized mice) as well as for screening of new antiretroviral compounds. The HIV-1 ANCHOR system can be extended to the study of other viruses or for the screening of antiviral compounds, e.g. against SARS-COV2.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 15/86 - Viral vectors

Abstract

An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 37/08 - Antiallergic agents

Abstract

The invention relates to a microfluidic device (10) comprising: - a support (20) comprising a substrate (25) made of an elastically deformable material; - a study chamber (30, 30a, 30b) extending inside the support (20) having at least one upper wall (32) at least partially formed by the substrate (25), at least one lower wall (34) and at least two side walls (33); - at least one substrate deformation chamber (40, 40a, 40b) at least partially formed by the substrate (25), fluidically independent of the study chamber (30, 30a, 30b) and at least partially extending inside the support (20) along one of the side walls (33) of the study chamber (30), the device being configured so that the deformation of the deformation chamber (40, 40a, 40b) causes the mechanical straining of at least one portion of the upper wall (32) in the study chamber (30).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The invention concerns a method implemented by computer means for visualizing at least a zone of an object in at least one interface, said method comprising the following steps: obtaining at least one image of said zone, said image comprising at least one channel, said image being a 2-dimensional or 3-dimensional image comprising pixels or voxels, a value being associated to each channel of each pixel or voxel of said image, a representation of said image being displayed in the interface, obtaining at least one annotation from a user, said annotation defining a group of selected pixels or voxels of said image, calculating a transfer function based on said selected pixels or voxels and applying said transfer function to the values of each channel of the image, updating said representation of the image in the interface, in which the colour and the transparency of the pixels or voxels of said representation are dependent on the transfer function.

IPC Classes  ?

• G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
• G06T 7/00 - Image analysis
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
• G06T 7/90 - Determination of colour characteristics
• G06T 11/00 - 2D [Two Dimensional] image generation
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

The present invention relates to a lentiviral vector, in particular a non-integrative lentiviral vector, comprising at least four distinct nucleic acid sequences encoding HPV antigens, to a lentiviral vector particle comprising said vector, to an isolated cell comprising the same, and to a vaccine composition comprising the said lentiviral vector, lentiviral vector particle or cell. The present invention further relates to their implementation in the treatment or prevention of an HPV induced cancer.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The invention relates to the discovery that TMPRSS2 acts as a functional receptor for HKU1. TMPRSS2 triggers HKU1 spike-mediated cell-cell fusion and viral pseudotype infection. Catalytically inactive TMPRSS2 mutants do not cleave spike but allow infection, demonstrating that HKU1 binding and processing represent two distinct functions of the receptor. TMPRSS2 binds with high affinity to HKU1 receptor binding domain (RED), but neither to OC43 nor to SARS-CoV-2. Conserved amino acids were identified within the RED that are essential for binding to TMPRSS2 and infection. Anti- TMPRSS2 VHH antibodies were generated that inhibit HKU1 spike binding to TMPRSS2, fusion and infection.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Nanoparticles comprising an antiretroviral drug such as AZT-TP or enfuvirtide encapsulated by a complex of chitosan and optionally a metal cation such as Fe3+, for use in treating or preventing HIV infection via subcutaneous or intramuscular administration. The nanoparticles have a size less than 300 nm and a high drug loading capacity between 20-60% by weight. They are prepared by mixing an aqueous solution of chitosan and metal cation with an aqueous solution of the drug. The chitosan-based nanoparticles provide an effective method to deliver antiretroviral drugs to key HIV reservoir sites with high drug loading and low toxicity.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• A61P 31/12 - Antivirals

Abstract

The invention relates to an isolated heterodimer of poxvirus A16 and G9 proteins as an immunogen in a subunit or nucleic acid vaccine against poxvirus. The invention provides an engineered heterodimer, nucleic acid encoding the heterodimer, neutralizing antibodies directed against said heterodimer and their use for the prevention, treatment and diagnostics of poxvirus infections and related diseases.

IPC Classes  ?

• A61K 39/285 - Vaccinia virus or variola virus
• C07K 14/07 - Vaccinia virusVariola virus
• A61P 31/20 - Antivirals for DNA viruses

Abstract

A computer-implemented and a device for analysis of a digital cytology slide of a biological sample. The biological sample having been previously collected from a subject suspected to be suffering from bladder cancer, the device including: at least one input configured to receive at least one digital cytology slide obtained from the biological sample; at least one processor configured to: detect cells of interest from the at least one digital cytology image; for each cell of interest, compute a features vector including at least one feature calculated on each cell of interest; define a bag of k instances for each digital cytology slide; calculating a global prediction score representative of a probability of presence of bladder cancer and/or a stage of bladder cancer for the subject; at least one output configured to provide the global prediction score.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06T 7/00 - Image analysis

Abstract

This invention thus relates to a computer-implemented and a device for analysis of a digital cytology slide of a biological sample, said biological sample having been previously collected from a subject suspected to be suffering from bladder cancer, said device comprising: at least one input configured to receive at least one digital cytology slide obtained from said biological sample; at least one processor configured to: detect cells of interest from said at least one digital cytology image; for each cell of interest, compute a feature vector comprising at least one feature calculated on each cell of interest; define a bag of k instances for each digital cytology slide; calculating a global prediction score representative of a probability of presence of bladder cancer and/or a stage of bladder cancer for said subject; at least one output configured to provide said global prediction score.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06T 7/00 - Image analysis
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

The present invention relates to novel tumor specific peptides derived from the translated ORF sequence from long noncoding RNA (lncRNA), and the uses thereof. The invention more particularly relates to the use of tumor specific peptides in cancer vaccines and cell therapy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to a recombinant protein comprising one or more fragments of pneumococcal surface protein A (PspA) and the adenylate cyclase (CyaA) from Bordetella species, especially Bordetella pertussis, wherein said PspA fragments are selected from clades 1 to 4, or a combination of two or more thereof. Additionally, the invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, especially a DNA sequence selected from the group consisting of nucleotide sequences as set forth in SEQ ID NOs: 12 to 18 and degenerate sequences thereof that encode a recombinant protein as set forth in SEQ ID NOs: 5 to 11 respectively. Further, an immunogenic composition comprising said recombinant protein or said expression cassette, and additionally a pharmaceutically acceptable carrier and/or adjuvant is disclosed. Finally, the invention relates to the use of said recombinant protein, or said expression cassette, or said immunogenic composition for the manufacture of a vaccine for preventing infections caused by Streptococcus pneumoniae, wherein said vaccine offers broad-spectrum protection against different pneumococcal isolates, regardless of serotypes.

IPC Classes  ?

• C07K 14/235 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bordetella (G)
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

System for detecting an antigen comprising: —a first fusion protein with no luciferase activity comprising: —a N-terminal domain which comprises a first single domain antibody which is directed against a first epitope of said antigen and —a C-terminal domain which comprises a first fragment of a luciferase having the amino acid sequence SEQ ID NO: 1 or is a variant thereof and —a second fusion protein with no luciferase activity comprising: —a N-terminal domain which comprises a second single domain antibody which is directed against a second epitope of said antigen and —a C-terminal domain which comprises a second fragment of a luciferase having the amino acid sequence SEQ ID NO: 2 or is a variant thereof. Luminescence is emitted in the presence of a substrate when both the first fusion protein and the second fusion protein bind to said antigen.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to combined antibodies against Sarbecoviruses, in particular Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS- CoV-2).

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COV-ID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The present invention further relates to the use of said AAV vector in the treatment of genetic hearing loss.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/86 - Viral vectors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to in vitro generation of organized 3D cell structures recapitulating various degrees of early organogenesis, including head-trunk embryo-like structures, using epigenetic remodeling factors. The invention relates in particular to methods of obtaining such organized 3D cell structures from mammalian cells, and to devices, in particular microfluidic platform, to perform such methods. The invention also concerns the use of the thus obtained 3D cell structures in applications of molecule screening, developmental testing, production of physiologically active substances and models for therapeutic investigation or use.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• A61K 35/54 - OvariesOvaOvulesEmbryosFoetal cellsGerm cells
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided herein are hantivirus antibodies. These hantivirus antibodies bind to the Gn and/or Gc subunits of a hantavirus glycoprotein and have broad neutralizing activity against an epitope of different hantavirus species. Such antibodies are used in methods of inducing an immune response and methods of inhibiting hantavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a single domain antibody directed against H2AX with a phosphorylation of serine at position 139 (γ-H2AX), a bivalent molecule comprising said single domain antibody and their use for detecting DNA damage and/or DNA replication stress.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

IPC Classes  ?

• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to the potentiation of aminoglycosides through activation of carbohydrate transporters, in particular using nucleosides. The invention encompasses the combination of a nucleoside and an aminoglycoside antibiotic for treating a bacterial infection, wherein the nucleoside enhances the killing of the bacteria by the antibiotic, preferably wherein the nucleoside limits the emergence of antibiotic-resistant bacteria or re-sensitizes antibiotic-resistant bacteria to the killing by the antibiotic.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.

IPC Classes  ?

• C12N 15/73 - Expression systems using phage lambda regulatory sequences
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 31/04 - Antibacterial agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• C07D 487/04 - Ortho-condensed systems
• G01N 21/76 - ChemiluminescenceBioluminescence
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

The present invention provides cationic peptoid/N-substituted peptidic copolymers, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful for the treatment of microbial infections.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/22 - Polypeptides or derivatives thereof
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The invention relates to a bacterial strain or a combination of bacterial strains, selected from the group consisting of: a Chryseobacterium massiliae strain, a Flavobacterium sp. strain with at least 95% or more Average Nucleotide Identity (ANI) value with the Flavobacterium sp. strain whose genome comprises SEQ ID NO: 1 or as identified by Accession Number No. I-5481 deposited at the Collection Nationale De Culture De Microorganismes (CNCM) on Jan. 24, 2020, and variants thereof, for use as a probiotic in fish(es). The bacterial strain(s) may has(ve) at least 95% or more Average Nucleotide Identity (ANI) value with the Chryseobacterium massiliae strain whose genome comprises SEQ ID NO:2 or as identified by Accession Number No. I-5479 deposited at the CNCM on Jan. 24, 2020, and/or the Flavobacterium sp. strain whose genome comprises SEQ ID NO: 1 or as identified by Accession Number No. I-5481 deposited at the CNCM on Jan. 24, 2020, respectively, or variants thereof. Probiotic use may be directed to preventing or minimizing infections by Flavobacterium columnare in fishes. The invention also concerns the said deposited bacterial strains, or probiotic compositions or food products or kits comprising the same, and a method to identify bacterial strain(s) that are probiotic against a pathogen infection.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/20 - Flavobacterium

Abstract

Provided are methods comprising expressing in a recombinant cell a recombinant error-prone reverse transcriptase (RT) and recombinant spacer RNA comprising a target sequence; making a mutagenized cDNA polynucleotide homologous to a DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising a target sequence, and recombinant recombineering system.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12R 1/19 - Escherichia coli

Abstract

The invention relates to compositions and methods for producing and using antibodies against the αlpha7 nicotinic acetylcholine receptor.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-pYP5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2-Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis-associated encephalopathy (SAE).

IPC Classes  ?

• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to variants of a DNA polymerase of the polX family capable of synthesizing a nucleic acid molecule without a template strand, or of a functional fragment of such a polymerase, comprising at least one mutation of a residue in at least one specific position, and to uses of said variants, in particular for the synthesis of nucleic acid molecules comprising 3′-OH modified nucleotides.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to a bacterial exopolysaccharide having a repeating structure comprising a series of repeating units represented by formula (I), and to the use of the bacterial exopolysaccharide for immunopotentiation. (In formula (I), n represents an integer of 0 or 1, independently for each repeating unit.)

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 37/04 - Immunostimulants
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12N 1/20 - BacteriaCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

IPC Classes  ?

• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (FcγRs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human FcγRs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab:hIgE immune complexes can induce anaphylaxis when injected in mice expressing human FcγRs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated. These variants did not induce anaphylaxis when injected into mice expressing human FcγRs and could be thus used for the treatment of IgE-mediated disease. Thus invention relates to a recombinant immunoglobulin heavy chain protein which comprises at least one mutation in the Fc portion and recombinant antibody comprising said heavy chain protein.

IPC Classes  ?

• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Provided are methods comprising expressing in a recombinant cell comprising a Cas gene a recombinant error-prone reverse transcriptase (RT) and a recombinant spacer RNA comprising a target sequence for mutagenesis of a DNA sequence in the Cas gene; making a mutagenized cDNA polynucleotide homologous to the DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence of the Cas gene in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant Cas protein, recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising the target sequence, and recombinant recombineering system.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/22 - Ribonucleases
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase. Compositions or kits comprising the pseudotyped lentiviral vector particles and a mammalian cell expressing an Angiotensin-converting Enzyme 2 (ACE2) protein. Methods of assaying for the presence of neutralizing antibodies against a SARS-CoV-2 S protein in a sample comprising antibodies by providing pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase; providing mammalian cells expressing an ACE2 protein; contacting the mammalian cells expressing the ACE2 protein with the pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein in the presence of a sample comprising antibodies; and assaying for the presence of a label in the mammalian cells.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 15/86 - Viral vectors
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The invention relates to an in vitro method of determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, comprising screening a biological sample of blood or plasma, where the level of at least two biomarkers selected amongst: PGK1, CFP, IGFALS, KRT19, SPRR1A, CPA4, CA2, SERPINA5, MAN2A1, KIF20B, SPEN, JUP, KRT6C, CDSN, KPRP, F13A1, SAA1 (SAA2), LBP, DSP, KRT2, KRT14, ARG1, S100A12, ATAD3B, MAN1A1, HAL, DCD, 07, HP, LEP, IL-8, IL-17, TNF-alpha, USF1, USF2, SELE, MSLN, EGFR, STATS and mtDNA level is determined, with the proviso that the selected biomarkers do not consist of the association of IL-8 and mtDNA level. The method may be for assessing the risk that a human patient has a non-atrophic gastritis (NAG), or an atrophic gastritis/pre-neoplasia (AG/P), or a gastric cancer (GO), or for discriminating between those risks or presence of these conditions. In a particular aspect, the method may comprise as a distinct, simultaneous or parallel step, a step of detecting an Helicobacter pylori infection. The invention also relates to a kit suitable for carrying out such a method, or a set of markers, and the use of the same for determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, or for prognosing or diagnosing a gastric pre-cancer condition or a gastric cancer condition.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention proposes a gene therapy approach as a potential curative treatment for the USHER syndrome, in particular for the USH1G syndrome, which is characterized by a profound deafness and a severe vestibular defect in humans. More precisely, the present invention concerns a gene therapy involving administering a vector expressing a SANS protein in a time window that is compatible with human ethics and welfare i.e., in post-natal, infant and adult humans in which the auditory system is completed. The present inventors herein show for the first time that it is possible to restore genetically-impaired auditory and vestibular functions in human beings in subjects suffering from an Usher1G syndrome even when the therapeutic vector is administered at this late stage.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/16 - Otologicals

Abstract

The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.

IPC Classes  ?

• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a lentiviral vector, in particular a non-integrative lentiviral vector, or a lentiviral vector particle, in particular a non-integrative lentiviral vector particle, for use for use in the treatment or prevention of an HPV induced cancer, the lentiviral vector comprising at least four distinct nucleic acid sequences; the lentiviral vector particle comprising at least one of the lentiviral vector; the lentiviral vector or the lentiviral vector particle being administered in combination with at least one immune checkpoint inhibitor.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/86 - Viral vectors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention allows a rapid and early diagnosis of bacterial or viral infection. Such a diagnosis is highly desired among patients admitted in emergency department to allow the initiation of the appropriate treatment. Although no biomarker alone can offer an appropriate diagnosis with sufficient sensitivity and specificity, the present invention defines optimal combinations of biomarkers allowing the diagnosis of infection.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

This disclosure provides proteins, DNA, and dsRNA to improve host-induced gene silencing (HIGS) and spray-induced gene silencing (SIGS) in plant/insect systems, by applying to said plants a composition inducing in same the expression of an Hsc70-4 protein, preferably of a Drosophila melanogaster Hsc70-4 protein.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides zwitterionic oligosaccharides, in particular fragments of the surface polysaccharides from Shigella sonnei and Shigella sonnei conjugates comprising them. The present invention also provides protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof, the disaccharide repeating unit of Shigella sonnei being: (I) The present invention provides zwitterionic oligosaccharides, in particular fragments of the surface polysaccharides from Shigella sonnei and Shigella sonnei conjugates comprising them. The present invention also provides protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof, the disaccharide repeating unit of Shigella sonnei being: (I)

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 39/112 - SalmonellaShigella
• A61P 31/04 - Antibacterial agents

Abstract

The invention relates to a bacteriophage targeting capsular-deficient Klebsiella pneumoniaee (Kp), comprising particular tail fiber polypeptides, which is capable of infecting at least two capsular- deficient Klebsiella pneumoniae of distinct O-types, in particular at least three distinct O-types of capsular-deficient Klebsiella pneumoniae. The invention also relates to a pharmaceutical composition comprising the same, a nucleic acid molecule having at least 99% of identity with the genomic sequence of the said bacteriophage, and the use of the said bacteriophage or composition(s) as a medicament, especially against an infection caused by at least one type of Klebsiella pneumoniae (Kp). The invention also relates to a method for decreasing the bacterial load of at least one Klebsiella pneumoniae (Kp) strain in the environment, making use of said bacteriophage.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention relates to Lichen planus (LP), and more specifically to no erosive form of LP (NELP). The invention provides an immune signature for LP, which is not found in other cutaneomucosal chronic inflammatory diseases. The invention moreover provides different diagnosis methods and methods of treating NELP, based on this immune signature. The inventors have indeed demonstrated the presence of HPV16-specific activated CTL in blood and lesion samples corresponding to the different clinical forms of LP, not only in erosive oral LP, while a different scenario operates in other cutaneomucosal chronic inflammatory diseases. This HPV16-specific activated CTL is characterized by TCRVβ3+ CD8+ T-cells oligoclonal expansions.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The inventors have now succeeded in developing compounds of Formula (I), described below, having the advantage of inhibiting NAD kinases, in particular P. aeruginosa NADK (PaNADK) enzyme, Listeria monocytogenes (LmNADK) enzyme and/or human cytosolic NADK (HsNADK) enzyme. The present invention relates to benzamide adenine dinucleoside compounds which are useful as inhibitors of NAD kinases, to pharmaceutical composition comprising such compounds, and to uses of such compounds in the treatment or prevention of bacterial infections.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

IPC Classes  ?

• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/28 - N-glycosides
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms